Adolescents ages 14 to 19 and young adults ages 20 to 24 had 86% and 71% lower prevalence of quadrivalent human papillomavirus vaccine serotypes, respectively, a decade after the HPV vaccine was introduced in the US, researchers reported in the Journal of Adolescent Health. The findings didn't show significantly reduced quadrivalent HPV vaccine serotypes among older age groups after vaccine introduction.
Vaccine introduction reduced HPV prevalence in teens, young adults
Sign up for Sigma Xi SmartBrief
News on scientific research and innovation
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.